LAUSR

Vaccines are critical cost‐effective tools to control the COVID‐19 pandemic. The heterologous prime‐boost vaccination has been used by many countries to overcome supply issues, so the effectiveness and safety of this strategy need to be better clarified. This study aims to verify the effect of heterologous prime‐boost COVID‐19 vaccination on healthcare professionals from Dante Pazzanese Hospital in Brazil. It was performed serological assays of vaccinated individuals after 2‐dose of CoronaVac (Sinovac; n = 89) or ChAdOx1 nCoV‐19 (Oxford‐AstraZeneca; n = 166) followed by a BNT162b2 booster (Pfizer‐BioNTech; n = 255). The serum antibodies anti‐S (spike), anti‐N (nucleocapsid), and anti‐RBD (receptor binding domain) were assessed by enzyme‐linked immunosorbent assay. The heterologous booster dose induced a 10‐fold higher anti‐Spike antibody regardless of the 2‐dose of a prime vaccine. It was strikingly observed that BNT162b2 enhanced levels of anti‐spike antibodies, even in those individuals who did not previously respond to the 2‐dose of CoronaVac. In conclusion, the heterologous scheme of vaccination using mRNA as a booster vaccine efficiently enhanced the antibody response against SARS‐CoV‐2, especially benefiting those elderly who were seronegative with a virus‐inactivated vaccine.